{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-cancer-care-pain/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"cd526925-546a-5aac-93eb-485967fb5fd7","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 56166fde-e3a3-45aa-bd56-3628a3774c25 --><h2>Changes</h2><!-- end field 56166fde-e3a3-45aa-bd56-3628a3774c25 -->","summary":null,"htmlStringContent":"<!-- begin item d0e87110-652b-41c4-8300-c029dc091bfa --><!-- begin field d6577b29-6f83-45b9-a022-1f3a3a529f3c --><p><strong>September 2020</strong> — minor update. Stable analgesic requirements were updated to highlight that fentanyl patches and buprenorphine patches are contraindicated in opioid-naive patients.</p><p><strong>July 2015 to October 2016</strong> — reviewed. Literature searches were conducted in September 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been structural changes to the topic and changes to the recommendations have been updated in line with NICE guidance <em>Care of dying adults in the last days of life </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-cancer-care-pain/references/\">NICE, 2015a</a>]. </p><!-- end field d6577b29-6f83-45b9-a022-1f3a3a529f3c --><!-- end item d0e87110-652b-41c4-8300-c029dc091bfa -->","topic":{"id":"bc60f031-53af-530c-93e6-59feeef85bcb","topicId":"305b6c55-5a1b-4817-87a1-c88490ac688b","topicName":"Palliative cancer care - pain","slug":"palliative-cancer-care-pain","lastRevised":"Last revised in September 2020","chapters":[{"id":"edd133a3-7ad6-5893-82e6-230eb9313dd3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6c915659-224b-530e-9fb3-c0b95720d118","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"362828da-ca6f-5900-8441-afd9ea44af5b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"cd526925-546a-5aac-93eb-485967fb5fd7","slug":"changes","fullItemName":"Changes"},{"id":"42928747-95fa-57d3-ae9e-7e3a6cf476a5","slug":"update","fullItemName":"Update"}]},{"id":"30edbf0f-7363-5f35-8126-77659a917fa3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"21b41383-eea4-5b71-8b34-687f05a65a5d","slug":"goals","fullItemName":"Goals"},{"id":"6ae0a52d-6ca2-5d97-8aa0-2beccf699f7e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d2aefa77-c551-539d-be41-67260cbe43ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bc8c749-a90c-532b-854e-5ee96116de81","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cf494151-3dcb-5990-851a-dd1cd70fab0c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9b0ea843-6c18-543c-b4f3-cbf22a737e5a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1078edd0-49b8-514b-aa1f-462d95bcb62c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"203a281c-b6df-5d53-a704-aae8df1662a6","slug":"definition","fullItemName":"Definition"},{"id":"7842468e-5e33-52dc-ade6-5149de1e1436","slug":"origins-of-pain","fullItemName":"Origins of pain"},{"id":"cc8e90f5-0cd6-54d0-9bec-75e0729d34b2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"288e99e9-418d-5e10-8b3b-94d111f68f63","fullItemName":"Management","slug":"management","subChapters":[{"id":"377406aa-05e6-5559-9f6e-4404453e407c","slug":"acute-severe-pain","fullItemName":"Scenario: Acute severe pain"},{"id":"3bc406e3-6db0-5386-a1a1-94f551e50a8d","slug":"assessment-of-pain","fullItemName":"Scenario: Assessment of pain"},{"id":"bfa2c711-266a-5133-a082-0655b9243bb5","slug":"managing-pain-non-emergency","fullItemName":"Scenario: Managing pain - non-emergency"},{"id":"fe447a1c-0019-5592-92ea-3d018c455b3b","slug":"managing-neuropathic-pain","fullItemName":"Scenario: Managing neuropathic pain"},{"id":"ffae5598-ad34-57a7-bb50-018dcb5f63c8","slug":"managing-intracranial-pressure-pain","fullItemName":"Scenario: Managing intracranial pressure pain"},{"id":"43317aee-6f8f-5d85-afed-94ec4c221bc5","slug":"managing-colic","fullItemName":"Scenario: Managing colic"},{"id":"4f3f67af-bf6a-5f02-84e4-c48ecc292167","slug":"managing-bone-pain","fullItemName":"Scenario: Managing bone pain"},{"id":"5c6257ce-9559-5775-a6e4-13eceaacff04","slug":"managing-muscle-spasm-pain","fullItemName":"Scenario: Managing muscle spasm pain"},{"id":"dba15959-96fa-5968-81ac-b3eb2b17604e","slug":"spinal-cord-compression","fullItemName":"Scenario: Spinal cord compression"},{"id":"d4083f8f-2904-55e8-9cb5-b20f6fcf10d2","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"}]},{"id":"32fe1b7d-4328-56b2-9102-e26bc06c421d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6452b6ef-626b-552e-bf5c-0c21daf91352","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2ca1fa6a-d245-53df-a4e5-79f63db752f1","slug":"codeine-dihydrocodeine-tramadol","fullItemName":"Codeine, dihydrocodeine and tramadol"},{"id":"9d55dc66-3dff-524e-9ed1-7919aeca221b","slug":"strong-opioids","fullItemName":"Strong opioids"},{"id":"47ef042e-05dc-576a-81b5-e9d12888c2e8","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"e39f9314-9fbb-5007-a7cf-c5ac3776546b","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"25156d8c-bb99-5e69-bf39-538e1a2c0265","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"58fbb7ca-b553-553e-8038-39021cfa2440","slug":"dexamethasone","fullItemName":"Dexamethasone"},{"id":"2e657be1-22f8-5617-85b0-b0d657de037e","slug":"diazepam","fullItemName":"Diazepam"},{"id":"d07c8c77-b362-533f-8d19-5397cdb2c2a6","slug":"baclofen","fullItemName":"Baclofen"},{"id":"e56de34b-8fb3-5a88-88fd-52f21822c95e","slug":"hyoscine-butylbromide","fullItemName":"Hyoscine butylbromide"}]},{"id":"ba95315f-c704-52b3-8e69-b66132db1afc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"36e5ad13-c74b-5b5b-a91a-dc99c76fe16c","slug":"drugs-to-treat-neuropathic-pain","fullItemName":"Drugs to treat neuropathic pain"}]},{"id":"e0efe998-f4e8-511b-9d28-24afd40c557e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"de1ea0e8-6fc9-51d7-85ca-027ba77b3439","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"db05b928-3724-5155-8572-4a5741697b59","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"ad310ea3-10a0-5123-a3cb-4623f775c2a6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ae075009-b5ea-57cb-9dab-2d35fa7facb1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"103ff2fc-2fa3-5785-a596-c4145bf1037f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"445d177d-22b8-5eef-aeaf-b7b0ae34c259","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"362828da-ca6f-5900-8441-afd9ea44af5b","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"fd4378b8-2a1e-5019-84ea-aa79595e855d","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 466f9cf0-987e-4732-850e-e8becb9efc04 --><h3>Previous changes</h3><!-- end field 466f9cf0-987e-4732-850e-e8becb9efc04 -->","summary":null,"htmlStringContent":"<!-- begin item be8e2d71-c74e-49c3-96d2-8a709bc82a43 --><!-- begin field d5eb8d96-a9e2-4370-9de1-b1d5c2d7082b --><p><strong>April 2015 </strong>— minor update. Update to the text to reflect a new law on drugs and impaired driving.</p><p><strong>July 2014</strong> — two minor updates:</p><ul><li>Update to the text to include advice from the MHRA regarding the safe use and disposal of fentanyl patches following reports of accidental exposures that have lead to life-threatening adverse effects.</li><li>Update to the text on the use of metoclopramide in palliative care. Although the European Medicines Agency has restricted the use of metoclopramide this does not apply to unlicensed uses of metoclopramide (for example palliative care).</li></ul><p><strong>June 2014 </strong>— minor update. Update to the text to reflect the fact that tramadol has been reclassified to a Schedule 3 controlled drug.</p><p><strong>January 2014 </strong>— minor update. Update to the text to correct a minor typographical error.</p><p><strong>July 2013 </strong>— minor update. Update to the text to reflect advice from the MHRA regarding diclofenac.</p><p><strong>June 2013 </strong>— reviewed. A literature search was conducted in May 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. There are no major changes to the recommendations.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>July 2011 </strong>— minor update. Text updated to include information on novel fentanyl products for breakthrough pain based on recommendations from the North East Treatment Advisory Group. Issued in September 2011.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>September 2010 </strong>— minor update. The choice of drug treatment for neuropathic pain has been updated in line with the NICE clinical guideline, <em>Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings</em>. Issued in September 2010.</p><p><strong>June 2010 to July 2010 </strong>— minor update. The advice on the management of breakthrough pain for people taking oral morphine has been updated. Issued in July 2010.</p><p><strong>December 2008 to March 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been no major changes to the recommendations.</p><p><strong>September 2008 </strong>— minor update to include advice from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding the safety of fentanyl patches. Issued in September 2008.</p><p><strong>June 2007 </strong>— minor update. Gabapentin is now licensed up to a maximum dose of 3600 mg per day for the treatment of peripheral neuropathic pain. Issued in June 2007.</p><p><strong>January 2006 </strong>— minor update. Prescriptions for diamorphine updated to reflect the change in handwriting requirements for controlled drug prescriptions. Issued in February 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>April 2005 </strong>— minor update to include new advice from the Committee on Safety of Medicines (CSM) on the safety of COX-2 selective inhibitors. Issued in April 2005.</p><p><strong>January 2004 </strong>— written. Validated in December 2004 and issued in February 2005.</p><!-- end field d5eb8d96-a9e2-4370-9de1-b1d5c2d7082b --><!-- end item be8e2d71-c74e-49c3-96d2-8a709bc82a43 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}